Skip to main content
All lobbying filings

RICCHETTI INCORPORATED

Lobbying for IPSEN BIOPHARMACEUTICALS, INC. · Biopharmaceutical company

 Filing 2nd Quarter - Termination
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$20,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts
Representation ended
Jun 30, 2025
The registrant reported terminating its work for this client.

Official filing document

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 842
    Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
  • S 339
    Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
 Lobbying activity 2
Pharmacy

Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)

Medicare/Medicaid

Issues related to coverage of diagnostic testing for cancer; H.R.842/S.339, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem